| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive Vice President, CFO
5 companies
David W Gryska is Director at FBRX and has filed Form 4s across 5 companies. David W Gryska's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $13.5M at current prices.
The biggest single holding is FBRX (~$11.4M) as Director.
David W Gryska has 15 Form 4 filings on record from July 2018 to October 2026, across 5 companies: Director at Celcuity (CELC), 2026; Director at Definium Therapeutics (DFTX), 2026; Director at Forte Biosciences (FBRX), 2023–2026, and 2 more.
The 19 reported transactions were 11 option or other derivative awards, 4 stock awards, 2 open-market purchases and 2 tax withholdings.
Counted by filing, the open-market trades come to 2 purchases worth about $39K and no sales.
The largest open-market purchase was 3,500 shares of MNMD at an average $5.98 on August 23, 2024, about $21K.